ADSL and peritonitis: Among them, II‐I4‐II (IIICRKPIICRKPIICRKPIICRKPIII‐NH2) had an excellent therapeutic effect in E. coli‐mediated mouse peritonitis model and significantly reduced inflammatory damage to organs (Figure 3E).[2] In combination with the performance of AMPs in experimental studies in vivo, long‐acting peptides are considered as the “golden target” for peptide therapy.